Drug intelligence / Profile preview

QG-11

Development stage: Preclinical
Lead developer: AceMapAI Biotechnology

Overview

QG-11 is an early-stage drug candidate currently in the preclinical development phase, sponsored by AceMapAI Biotechnology (also known as QureGenAI). The molecule was identified and developed using the company's proprietary AI-driven drug discovery platform, which focuses on de novo design and lead optimization. As of current pipeline disclosures, QG-11 is classified as a 'Lead' asset. However, specific details regarding its molecular modality (e.g., small molecule vs. biologic), biological target, and primary therapeutic indications have not been publicly released by the developer.

Beyond the preview

Go deeper on QG-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QG-11.

Explore the full profile